Mon Jun 23 11:50:00 UTC 2025: Here’s a summary of the text, followed by a news article rewrite:

**Summary:**

Eli Lilly’s stock is up due to strong initial sales of its weight-loss drug Mounjaro in India. Mounjaro, introduced in March, has already sold over 81,570 units, generating 239.4 million rupees ($2.76 million) in revenue and experiencing a 60% sales increase between April and May. This success is attributed to India’s growing rates of obesity and diabetes, coupled with Lilly’s mass-market pricing strategy. However, competition is expected to increase as Indian drugmakers prepare to launch cheaper versions of weight-loss drugs, and Novo Nordisk plans to launch Wegovy in India next year. Analysts generally rate LLY stock as a Strong Buy, with a potential upside of 27.08%.

**News Article:**

**Eli Lilly Shares Surge on Strong Mounjaro Sales in India**

**NEW YORK, NY -** Shares of Eli Lilly (LLY) experienced a boost today following the news of robust initial sales of its weight-loss drug Mounjaro in India. According to data from PharmaTrac, Mounjaro has sold over 81,570 units in the country since its launch in March, generating approximately 239.4 million rupees ($2.76 million) in revenue. Sales figures jumped 60% between April and May, indicating a rapidly growing demand for the drug.

Lilly beat out competitor Novo Nordisk (NVO) to introduce its diabetes and weight-loss medication to the Indian market, which is grappling with increasing rates of obesity and diabetes. Government surveys indicate a rising percentage of overweight or obese adults, and projections from the International Diabetes Federation estimate that the number of adults with diabetes in India will surpass 124 million by 2045.

PharmaTrac suggests Mounjaro’s mass-market pricing could make it a key player in the Indian obesity and diabetes management market, estimated to be worth $150 billion by the early 2030s. Eli Lilly has confirmed a “positive” response to Mounjaro in India and stated that it is focused on meeting the growing demand.

However, the company faces increasing competition. Local Indian drugmakers are preparing to launch cheaper, generic versions of weight-loss drugs, and Novo Nordisk is slated to introduce its own weight-loss drug, Wegovy, in India next year.

Despite the impending competition, analysts remain optimistic about LLY stock. TipRanks data shows a Strong Buy consensus rating based on 17 Buy, 2 Hold, and 1 Sell ratings, with a consensus price target of $997.60, implying a 27.08% upside for the stock.

Read More